chronic lymphocytic leukaemia draft london cancer...

23
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

Upload: others

Post on 28-Dec-2019

6 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

%%%

!!!

&8*"#-(%!9:;8"(9<-(%!),='):-'%+,-$).-#)/!

!!!!

!""#$%&'()*(+,-./,*(0$,#'(1$#(2,&3,-$4$567,4(8,4659,976&:(!!

"##$%&'()&'*!!(+),#$-!>':-*%?@*'A'.B%C'*<D/%E)'.<8%FE>G!%.()/!#0!&11+/-!2342546275!!8/$1&#'!'+9:/$-!;742!!G8)/)%@,-$).-#)/%/8",.$%H)%*)'$% -#%("#I,#(<-"#%A-<8% <8)% .'<)/<%F'<-"#'.%&'#()*%J*,@%K,#$%-#L"*:'<-"#B%'#$%'..%';;.-('H.)%#'<-"#'.%M-#<)*#'<-"#'.%@,-$'#()7%%

%

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

!! !

Page 2: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

2

",$#'&<!=>9?,#<>)&<!=/+@(/9&(!A"==B!!

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

• N#%,;%<"%U1V%"L%;'<-)#</%<8)%$-'@#"/-/%"L%&!!%-/%'#%-#(-$)#<'.%L-#$-#@%"#%KC&%%• G8)% $-'@#"/-/% "L% &!!% -/% (,**)#<.9% H'/)$% "#% <8)% (":H-#'<-"#% "L% .9:;8"(9<)%

:"*;8"."@9B% <8)%;*)/)#()%"L% \3Y21]M.% (-*(,.'<-#@% (."#'.%C% ()../% ;)*/-/<-#@% L"*% <8*))%:"#<8/%'#$%'%(8'*'(<)*-/<-(%-::,#";8)#"<9;)7%

• &!!% ()../% <9;-('..9% )Y;*)//% A)'=% <"% A)'=4:"$)*'<)% :"#"<9;-(% /,*L'()%-::,#"@."H,.-#% W>N@XB% &J3B% &J2]B% &J0RB% &J251% WK'**)#% "#! $%&! 0122X% '#$% A)'=% "*%'H/)#<% &JU]CB% &J00% '#$% KT&U7% ?% *)("::)#$)$% ;'#).% "L% :"#"(."#'.% '#<-H"$-)/%'#$%/("*-#@%/9/<):%L"*%<8)%$-'@#"/-/%"L%&!!%-/%/8"A#%H)."A7%%%• T'*=)*% • >("*)%2% • >("*)%1%• >:N@%• &J3%• &J0R%• KT&U%• &J00%"*%&JU]C%

• O)'=4:"$)*'<)%

• Q"/-<-6)%• Q"/-<-6)%• F)@'<-6)%• O)'=%

• ><*"#@%• F)@'<-6)%• F)@'<-6)%• Q"/-<-6)%• ><*"#@%

• >("*)% \% R% /,@@)/<-6)% "L% &!!Z% /("*)% ^% R% /,@@)/<-6)% "L% "<8)*% C% ()..%:'.-@#'#(9%

%• _/-#@%<8-/%/("*-#@%/9/<):B%]0V%"L%&!!%('/)/%/("*)%S%"*%3B%5V%/("*)%R%'#$%0V%/("*)%2%

"*%0Z%'..%C%()..%.9:;8":'/%/("*)%2%"*%07%• &J3%;"/-<-6-<9%-/%;*)/)#<%-#%\]1V7%%NL%&J3%#)@'<-6)%("#/-$)*%'.<)*#'<-6)%$-'@#"/)/7%• ?#%'.<)*#'<-6)% `:-#-% /("*)aB% -#("*;"*'<-#@%&J3B% &J0R% '#$%&J251% ('#% './"% H)%,/)$%

WK'**)#%"#!$%&!0122X7%• Q'<-)#</%A-<8%'%(."#'.%.9:;8"(9<)%(",#<%H)<A))#%R%'#$%3%Y%21%]M.B%-#%<8)%'H/)#()%"L%

.9:;8'$)#";'<89B%/;.)#":)@'.9%"*%(9<";)#-'/B%'*)%(.'//-L-)$%'/%<L&'&<(L!9#'#<L#'(L!MN!L>9?,#<>)#1&1%AOM=B%A-<8%'%*-/=%"L%;*"@*)//-"#%<"%&!!%"L%240V%;)*%9)'*7%

!! !

Page 3: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

3

.&00/$/')&(L!.&(*'#1&1!!• K9(LL!L>9?,#<>)&<!L>9?,#9(!AK==B!G8)%OEb% (.'//-L-('<-"#% "L% <8)%:'.-@#'#<% .9:;8";*".-L)*'<-6)% $-/"*$)*/% S% -#$-('<)% <8'<% &!!%'#$%>!!%'*)% -$)#<-('.%$-/)'/)/7% %E"A)6)*B%<8)*)%:'9%H)%$-LL)*)#()/% -#%'$8)/-"#%:".)(,.)/B%A8-(8%'*)%*)/;"#/-H.)%L"*%$-LL)*)#()/%-#%<-//,)%$-/<*-H,<-"#7%G8)%$)L-#-<-"#%"L%>!!%*)P,-*)/%<8)%;*)/)#()% "L% .9:;8'$)#";'<89% '#$M"*% /;.)#":)@'.97% T"*)"6)*B% <8)% #,:H)*% "L% C%.9:;8"(9<)/% -#% <8)% ;)*-;8)*'.% H.""$% /8",.$% #"<% )Y())$% 3% c% 21]M!7% N#% >!!B% <8)% $-'@#"/-/%/8",.$%H)%("#L-*:)$%H9%8-/<";'<8"."@9%"L%'%.9:;8%#"$)%H-";/97%• O(')L/!</LL!L>9?,#9(!T"*;8"."@-('..9B%:'#<.)%()..%.9:;8":'%WT&!X%%('#%H)%$-LL-(,.<%<"%$-LL)*)#<-'<)%L*":%'<9;-('.%&!!B%H,<%(.'//-('..9%()../%'*)%;.)":"*;8-(%/:'..%.9:;8"(9<)/%A-<8%-**)@,.'*%"*%(.)'6)$%#,(.)-7%!-=)%&!!B%&J3%)Y;*)//-"#%-/%(8'*'(<)*-/<-(B%A8)*)'/%&J0R%-/%<9;-('..9%#)@'<-6)7%G8)%)Y();<-"#%-/%T&!%-#%.),='):-(%;8'/)B%A8)*)%&J0R%)Y;*)//-"#B%'.H)-<%'<%."A%.)6)./B%"((,*/%-#%,;<"%"#)%<8-*$%"L%('/)/%WK'**)#%"#!$%&!0122X7%_#.-=)%C4&!!B%()../%-#%T&!%/<'-#%/<*"#@.9%L"*%(9(.-#%J2%'#$%>N@7%G8)%<W22Z2SX%-/%(8'*'(<)*-/<-('..9%-$)#<-L-)$7%• =>9?,#?L(19(<>)&<!L>9?,#9(%WO'.$)#/<*":D/%T'(*"@."H,.-#'):-'X%%• P(&$>!</LL!L/+@(/9&(!• =($*/!*$('+L($!L>9?,#<>)/!L/+@(/9&(!• O><#1&1!0+'*#&%/1!• I%+L)!E!</LL!L>9?,#9(!L/+@(/9&(!• Q$#L>9?,#<>)&<!L/+@(/9&(!Q*".9:;8"(9<)/% '*)% .'*@)% ()../% A-<8% /":)A8'<% -::'<,*)4';;)'*-#@% #,(.)'*% (8*":'<-#B% '%;*":-#)#<% 6)/-(,.'*% #,(.)".,/B% '#$% 'H,#$'#<% (9<";.'/:7% % b<8)*% L)'<,*)/% -#(.,$)%:'//-6)%/;.)#":)@'.9%'#$%89;)*.9:;8"(9<"/-/%W,/,'..9%\%211%Y%21%]M!X7%%%• Q8)#"<9;-('..9B%;*".9:;8"(9<)/%:'9%H)%)-<8)*%C4()../%"*%G4()../%'#$%'*)%$-/<-#(<%L*":%&!!%

.9:;8"(9<)/B%8'6-#@%#"*:'.%':",#</%"L%>:N@%'#$%#)@'<-6-<9%L"*%&J37%• C4Q!!%-/%,/,'..9%&J2]B%&J01B%&J02%'#$%&J0S%;"/-<-6)7%• G4Q!!%6'*-'#</%'*)%&JSdM&Je4%W53%VXB%&JSdM&Jed%W02%VXB%"*%&JS4M&Jed%W2R%VX7%G8)%)#<-<9%

L"*:)*.9%('..)$%G4&!!%-/%#"A%('..)$%G4Q!!7%T"*;8"."@-('..9B%G4Q!!%()../%'*)%/:'..)*B%8'6)%:"*)% ("#$)#/)$% #,(.)'*% (8*":'<-#B% #,(.)'*% -**)@,.'*-<9B% "L<)#% -#("#/;-(,",/% #,(.)".-%'#$%(9<";.'/:-(%H.)HH-#@7%

!!.&1)&'*+&1,&'*!:/)R//'!"==S!OM=!('%!K==!%

"$&)/$&(! "==! OM=! K==!&."#'.%C%()../%\3%Y%21]M!% f% F% F%J-/)'/)4*).'<)$%(9<";)#-'/% fMF% F% fMF%C%/9:;<":/% fMF% F% fMF%!9:;8'$)#";'<89%'#$M"*%/;.)#":)@'.9% fMF% F% f%%%! !

Page 4: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

4

T8I=HIECGD!ID.!CD8TKECJIECGDK!IE!QFTKTDEIECGD!W-#(.,$-#@%'/9:;<":'<-(%><'@)%?%;'<-)#</%'<%$-'@#"/-/X%%• E-/<"*9%"L%-#L)(<-"#/B%C%/9:;<":/g%A)-@8<%."//B%#-@8<%/A)'</B%L)6)*B%)Y<*):)%.)<8'*@9%• K':-.9%8-/<"*9%"L%.9:;8"-$%:'.-@#'#(9%• h&b+%/("*)%• Q89/-('.%)Y':-#'<-"#%L"*%.9:;8'$)#";'<89M%/;.)#":)@'.9M%8);'<":)@'.9%%>':;.)/%/)#<%<"%>NETJ>%L"*g%! KC&%i%L-.:%! J?G% '#$% *)<-(,."(9<)% (",#<% W)//)#<-'.% -#% '..% '#'):-(% ;'<-)#</% '#$% H)L"*)% /<'*-#@%

<*)'<:)#<X%! Q)*-;8)*'.%H.""$%-::,#";8)#"<9;)%! _ihB%(*)'<-#-#)B%,*'<)B%('.(-,:B%;8"/;8'<)%! !-6)*%L,#(<-"#%<)/</%! !JE%! N::,#"@."H,.-#%.)6)./B%/)*,:%;*"<)-#%).)(<*";8"*)/-/%! C)<'40%:-(*"@."H,.-#%Wj0TX%%?$$-<-"#'.%N#6)/<-@'<-"#/%<"%("#/-$)*%! KN>E%(9<"@)#)<-(% '#'.9/-/% 4% ;)*-;8)*'.%H.""$% W-#%8);'*-#%"*% (9<"@)#)<-(%:)$-,:X% -/% <8)%

;*)L)**)$%:'<)*-'.7%! Q)*-;8)*'.%H.""$%L"*%N@Ek%:,<'<-"#%'#'.9/-/%! C"#)% :'**"A% WCTX% '/;-*'<)% i% <*);8-#)7% N#% <8)% )*'% "L% KN>E% '#'.9/-/B% *",<-#)% CT%

(9<"@)#)<-(/% -/% #"<% *)("::)#$)$7% M#'/! 9($$#R! &1! '#)! /11/')&(L! ()! %&(*'#1&1! :+)!1,#+L%! :/! ?/$0#$9/%! ?$&#$! )#! ),/$(?>! ('%! )#! %/0&'/! <#9?L/)/! $/1?#'1/! (0)/$!)$/()9/')4! ! C)! &1!(L1#! &'%&<()/%! &'!%/)/$9&'&'*!),/!<(+1/!#0!<>)#?/'&(1!?$/N)$/()9/')!('%!?$#L#'*/%!<>)#?/'&(1!?#1)!)$/()9/')!AM"KP!6276B4!

%! !9:;8%#"$)%H-";/9% % 4% -L% <8)%$-'@#"/-/% -/%,#()*<'-#%"*% <"%)Y(.,$)% <*'#/L"*:'<-"#% W)@B% -L%

<8)*)%-/%,#,/,'..9%H,.=9%.9:;8'$)#";'<89X%! &G%/('#%"L%#)(=B%(8)/<B%'H$":)#%'#$%;).6-/7%G8-/%-/%@)#)*'..9%#"<%)//)#<-'.%'<%$-'@#"/-/B%

H,<% -/% *)P,-*)$% ;*)4<*)'<:)#<% <"% '.."A% ;"/<% <8)*';9% '//)//:)#<7% G8)*)% -/% #"% *".)% L"*%*",<-#)%/,*6)-..'#()%&G%/('#/%-#%'/9:;<":'<-(%;'<-)#</%;"/<%<*)'<:)#<7%

! NL%,#$)*%("#/-$)*'<-"#%L"*%'.):<,l,:'H%<8)*';9B%H'/).-#)%&Tk%/)*"/<'<,/%! E!?%<9;-#@%%WL"*%;'<-)#</%A8)*)%'#%'.."@)#)-(%<*'#/;.'#<%:'9H)%'#%";<-"#X%

%%Q$&#$!)#!)$/()9/')!%! E);'<-<-/%C%W-#(.,$-#@%E);C/%?@B%E);C/?HB%E);C(%?HX%! E);'<-<-/%&%?H%! ENk%/)*"/<'<,/%! KN>E% (9<"@)#)<-(% '#'.9/-/B% /;)(-L-('..9B% /(*))#-#@% L"*% '()% '#$% (*+,% $).)<-"#% '#$M"*%

:,<'<-"#%/8",.$%H)%;)*L"*:)$%;*-"*%<"%<*)'<:)#<%W'#$%*);)'<)$%'<%*)4<*)'<:)#<X%!!

Page 5: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

5

"=CDC"I=!KEIJCDJ!!><'@-#@% -/% H'/)$% "#% (.-#-('.% ;'*':)<)*/% '#$% #"<% "#% /;)(-'.-/<% -#6)/<-@'<-"#/7% GA"% /<'@-#@%/9/<):/%'*)%,/)$Z%C-#)<%'#$%['-7%%%%

O#%&0&/%!F(&!"L&'&<(L!K)(*&'*!K>1)/9!U#$!"==!

F&1@! K)(*/! ./1<$&?)&#'! O/%&('!1+$;&;(L!

!"A% 1% !9:;8"(9<"/-/% -#% H.""$% "*% H"#)%:'**"A%

231%:"#<8/%

N#<)*:)$-'<)%

N%%%NN%

!9:;8"(9<"/-/%d%)#.'*@)$%.9:;8%#"$)/%

%

!9:;8"(9<"/-/% d% )#.'*@)$% .-6)*% "*%/;.))#% A-<8% "*% A-<8",<%.9:;8'$)#";'<89%%

%212%:"#<8/%%%U2%:"#<8/%%%

E-@8% NNN%%%%Nk%

!9:;8"(9<"/-/% d% '#'):-'% WEH%^22@M$.X%A-<8%"*%A-<8",<%)#.'*@)$%.-6)*B%/;.))#B%"*%.9:;8%#"$)/%!9:;8"(9<"/-/% d% <8*":H"(9<";)#-'% W;.'<).)<%(",#<%211%Y%21%]M.X%A-<8%"*%A-<8",<%'#'):-'%"*%)#.'*@)$%.-6)*B%/;.))#B%"*%.9:;8%#"$)/%%

%%%]%:"#<8/%

G8)%['-%>9/<):%8'/%H))#%:"$-L-)$%<"%("#/-/<%"L%<8*))%@*",;/%• !"A%*-/=%m%['-%/<'@)%1%• N#<)*:)$-'<)%*-/=%m%['-%/<'@)/%N%'#$%NN%(":H-#)$%• E-@8%*-/=%m%['-%/<'@)/%NNN%'#$%Nk%(":H-#)$%

%

!C-#)<%/<'@)%?%;'<-)#</%A8"%8'6)%EH%\21@M$.B%!9:;8"(9<)/%^%R1Y21]M.B%:-#-:'.%"*%#"%.9:;8'$)#";'<89B%#"#4$-LL,/)% ;'<<)*#% "L% CT% -#6".6):)#<% '#$% '% .9:;8"(9<)% $",H.-#@% <-:)% "L% \% 20%:"#<8/% 8'6)% '% e1V% (8'#()% "L%H)-#@%'.-6)%'<%21%9)'*/%'#$%"#.9%23V%'*)%.-=).9%<"%*)P,-*)%<*)'<:)#<7%%

M&'/)!K)(*&'*!K>1)/9!U#$!"==%

%%%?% GA"%"*%.)//%.9:;8"-$%'*)'/%)#.'*@)$n%

%%%C% G8*))%"*%:"*)%.9:;8"-$%'*)'/%)#.'*@)$%

%%%&% Q*)/)#()%"L%'#'):-'%WEH%^21@M$.X%"*%<8*":H"(9<";)#-'%W;.'<).)<%(",#<%^211%Y%21%]M.X%

n%K-6)%.9:;8"-$%H)'*-#@%'*)'/%'*)%;"//-H.)g%()*6-('.B%'Y-..'*9B%-#@,-#"4L):"*'.B%/;.))#B%'#$%.-6)*%WA8)<8)*%,#-.'<)*'.%"*%H-.'<)*'.B%)'(8%'*)'%-/%(",#<)$%'/%"#)X7%><'@)%?%Q*"@*)//-6)%-/%(8'*'(<)*-/)$%H9%'<%.)'/<%"#)%"L%<8)%L".."A-#@g%

• ?%;)*/-/<)#<%*-/)%-#%<8)%.9:;8"(9<)%(",#<%A-<8%$",H.-#@%<-:)%^20%:"#<8/%• ?%$"A#A'*$%<*)#$%-#%<8)%EH%'#$M"*%;.'<).)</%• 31V%-#(*)'/)%-#%<8)%/-l)%"L%<8)%.-6)*%'#$M"*%/;.))#%'#$M"*%#"$)/7%%?;;)'*'#()%"L%

.9:;8'$)#";'<89B%8);'<":)@'.9%"*%/;.)#":)@'.9%-L%#"<%;*)6-",/.9%;*)/)#<7%• C%/9:;<":/g%;9*)Y-'B%#-@8<%/A)'</B%A)-@8<%."//B%)Y<*):)%.)<8'*@9%

Page 6: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

6

QFGJDGKEC"!UTIEHFTK!

U(<)#$1!(00/<)&'*!?$#*'#1&1!

%%[)("@#-/)$%;""*%;*"@#"/<-(%L'(<"*/%-#(.,$)g%

• ?$6'#()$%/<'@)%%• T'.)%@)#$)*%%• Q)*-;8)*'.% H.""$% .9:;8"(9<)% $",H.-#@% <-:)% ^20% :"#<8/%WJ",H.-#@% <-:)% L"*%

.9:;8"(9<)/% o% W-#-<-'.% .9:;8"(9<)% (",#<XYW#"7% "L% :"#<8/% H)<A))#% (",#</XM%W$-LL)*)#()%H)<A))#%/)("#$%'#$%-#-<-'.%.9:;8"(9<)%(",#<X%%

• >)*,:% :'*=)*/7% !JEB% &J0RB% <89:-$-#)% =-#'/)B% '#$% j04:-(*"@."H,.-#% :'9% ;*)$-(<%/,*6-6'.%"*%;*"@*)//-"#4L*))%/,*6-6'.%

• p?QU1%)Y;*)//-"#%H9%&!!%()../%• &JRe%)Y;*)//-"#%H9%&!!%()../%%• T,<'<-"#'.% /<'<,/% "L% N@Ek7% G8)% ",<(":)% "L% ;'<-)#</% A-<8% &!!% ()../% <8'<% ,/)% '#%

,#:,<'<)$%N@Ek%@)#)%-/%-#L)*-"*%<"%<8"/)%;'<-)#</%A-<8%'%:,<'<)$%N@Ek%@)#)%WJ':.)%)<%'.%2]]]Z%E':H.-#%)<%'.%2]]]X7%N#%'$$-<-"#B%<8)%EkR402%@)#)%,/'@)%-/%'#%,#L'6"*'H.)%;*"@#"/<-(%:'*=)*%-#$);)#$)#<%"L%:,<'<-"#'.%/<'<,/%WG"H-#%)<%'.%0110X7%

• [)/;"#/)% <"% <*)'<:)#<7%T[J% ('#% H)% '//)//)$% ,/-#@% Q&[% "*% :,.<-4;'*':)<)*% L."A%(9<":)<*97% Q'<-)#</% A8"% '(8-)6)% T[J4#)@'<-6)% /<'<,/% ';;)'*% <"% 8'6)% '% H)<<)*%;*"@#"/-/% <8'#% <8"/)% A-<8",<% '#$% L'-.,*)% <"% '(8-)6)% T[J4#)@'<-6-<9% ;*)$-(</% L"*%*).';/)%WT"*)<"#%)<%'.%%0113X7%

• &9<"@)#)<-(%'H#"*:'.-<-)/%%

_;%<"%e1V%"L%;'<-)#</%8'6)%)6-$)#()%"L%(9<"@)#)<-(%'H#"*:'.-<9%,/-#@%-#<)*;8'/)%KN>E%'#$%:,/<%H)%;)*L"*:)$%H)L"*)%/<'*<-#@%<*)'<:)#<7%?$$-<-"#'.%@)#)<-(%$)L)(</%:'9%H)%'(P,-*)$%$,*-#@% <8)%(",*/)%"L% <8)%$-/)'/)B% <8)*)L"*)B%KN>E%'#'.9/-/% /8",.$%H)%*);)'<)$%H)L"*)%)'(8%.-#)%"L%<*)'<:)#<7%%

Q()&/')!$/L()/%-! ?@)%! +)#$)*%! Q)*L"*:'#()%/<'<,/%! &"4:"*H-$-<-)/%.&1/(1/!$/L()/%-! J-/)'/)%/<'@)%! T'**"A%L'-.,*)%! N::,#"$)L-(-)#(9M',<"-::,#-<9%! !9:;8":'<",/%<*'#/L"*:'<-"#%! C-":'*=)*/%)7@7%!JE%N@Ek%:,<'<-"#%/<'<,/B%C0T%E$/()9/')!$/L()/%-! G9;)%"L%<*)'<:)#<%! [)/;"#/)M<"Y-(-<9%! T[J%/<'<,/7%

Page 7: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

7

%

?H#"*:'.-<9% N#(-$)#()% &"::)#</%

2RP4% 2S4S1V% +""$% ;*"@#"/-/B% :)$-'#%/,*6-6'.%2RR%:"#<8/%

22P4%W?GTX% 214R0V% T'.)%@)#$)*B%9",#@)*%'@)B%H,.=9%!F/%

T)$-'#% /,*6-6'.% U]% :"%A-<8% ("#6)#<-"#'.%(8):"<8)*';9B%H,<%%:'9%%

K&[% ';;)'*/% <"% "6)*(":)%<8-/%;""*%;*"@#"/-/%WE'..)=%)<%'.%0121X%

G*-/":9%20% 01V% T'9% H)% '//"(-'<)$% A-<8% '%;""*)*%;*"@#"/-/%%

2U;4%WQ3RX%

W(*+,%."//%"*%:,<'<-"#X%

3421V%;*)%2/<%[Y%

R1V% -#% K.,$'*'H-#)% m%*)L*'(<"*9%;'<-)#</%

Q""*% *)/;"#/)% <"%("#6)#<-"#'.%(8):"<8)*';9B% :)$-'#%/,*6-6'.%R0%:"#<8/7%%

5P4% 04]V% Q.'/:'(9<"-$% L)'<,*)/%("::"#B% -#<)*:)$-'<)%;*"@#"/-/%%

%

FC% ?%/:'..%/,H/)<%"L%><'@)%?%;'<-)#</%A-<8%(*+,%'H#"*:'.-<-)/%A-..%8'6)%/<'H.)%$-/)'/)%WC)/<%"#!$%B%011]Z%G':%"#!$%B%011]X7%

?.<8",@8% <8)*)% -/%#"%(,**)#<%)6-$)#()% <8'<%;*"@#"/<-(%$'<'%/8",.$% -#L.,)#()% <8)% <-:-#@%"L%-#-<-'.%<8)*';9%-#%-#$-6-$,'.%;'<-)#</B%-<%$")/%"LL)*%-#/-@8<%-#<"%<8)%.-=).9%#'<,*'.%8-/<"*9%"L%<8)%$-/)'/)B%A8-(8%:'#9%;'<-)#</%6'.,)7%

%

• M"KP!J+&%/L&'/1!6276-%

O/(1+$/9/')!#0!?$#*'#1)&<!:&#9($@/$1! &1!'#)! <+$$/')L>! $/<#99/'%/%! 0#$!?()&/')1!R&),!/($L>!"==!&'!R,#9!),/$/!&1!'#!<L&'&<(L!&'%&<()&#'!0#$!)$/()9/')4!

C%/')&0>&'*!(!;+<=!(:'#$9(L&)>!&'!?()&/')1!R&),!'#!<L&'&<(L!&'%&<()&#'!0#$!),/$(?>!&1!'#)!('!&'%&<()&#'!0#$!)$/()9/')!AJFI.T!M7B4!

%

Page 8: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

8

%34!Q()&/')!&'0#$9()&#'!('%!1+??#$)S!$#L/!#0!"DK!('%!IPQ!

%NL% <8)% $-'@#"/-/% "L% &!!% -/% ()*<'-#B% ;'<-)#</% /8",.$% H)% -#L"*:)$% <8'<% &!!% -/% '% ('#()*% "L% <8)%C.""$B%C"#)%T'**"A%'#$%N::,#)%>9/<):7%T"/<%;'<-)#</%A-..%#"<%*)P,-*)%<*)'<:)#<%'<%<8)%<-:)%"L% $-'@#"/-/7% G8)-*% ;*"@#"/-/B%A8-(8% -/% 6)*9% 6'*-'H.)B% /8",.$% H)% $-/(,//)$% '."#@%A-<8%;"//-H.)% <*)'<:)#<% ";<-"#/% '#$% (.-#-('.% <*-'./% "*% *)/)'*(8% /<,$-)/% (,**)#<.9% '6'-.'H.)B% '/%';;*";*-'<)7%!?..%;'<-)#</%:,/<%8'6)%'(()//%<"%'%q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b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

Page 9: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

9

%Q'*<-(,.'*.9%-:;"*<'#<%'/;)(</%"L%("::,#-('<-"#%'#$%;'<-)#<%-#L"*:'<-"#%-#%&!!%-#(.,$)%<8)%#))$%<"%'$$*)//%<8)%<9;-('..9% -#(,*'H.)%#'<,*)%"L%<8-/%$-/)'/)%'#$%<8'<% -<%:'9%H)%:'#'@)$%<8*",@8% <8)% )Y;)(<'#<% `A'<(8% '#$% A'-<a% ';;*"'(8% '#$% #)6)*% *)P,-*)% <*)'<:)#<% "*B%'.<)*#'<-6).9B%:'9%*)P,-*)%/)6)*'.%<*)'<:)#<%(",*/)/7%%%G8)%-#'H-.-<9%<"%$)L-#-<-6).9%;*)$-(<%A8)#%"*%)6)#%-L%<*)'<:)#<%:'9%H)%';;*";*-'<)%('#%H)%'%;'*<-(,.'*.9% $-LL-(,.<% ("#();<% L"*% ;'<-)#</% <"% ,#$)*/<'#$% '#$% '(();<7% G8-/% /8",.$% H)%'(=#"A.)$@)$B% '(("::"$'<)$% '#$% '$$*)//)$% '/% ';;*";*-'<)% -#% )'(8% ;'<-)#<D/% -#$-6-$,'.%:'#'@):)#<%';;*"'(8%!O*-<<)#%'#$% 6)*H'.% -#L"*:'<-"#% -/% )//)#<-'.% '#$% <8)%q)9%O"*=)*% M% &F>%;.'9/% '% =)9% *".)% -#%)#/,*-#@% <8'<% ;'<-)#</% 8'6)% '(()//% <"% ';;*";*-'<)% '#$% *).)6'#<% A*-<<)#% -#L"*:'<-"#%*)@'*$-#@% <8)-*% ("#$-<-"#% 7% G8)% &F>Mq)9% O"*=)*% /,;;"*</% <8)% ;'<-)#<% L*":% $-'@#"/-/B%<8*",@8",<%<8)%<*)'<:)#<%;'<8A'9B% -#(.,/-6)%"L%)#$4"L4<*)'<:)#<B% .'<)4)LL)(</%'#$%)#$4"L4.-L)%('*)7%%G8)%&F>Mq)9%O"*=)*%'(</%'/%;'<-)#<%'$6"('<)%'#$%-/%;*)/)#<%-#%<8)%TJG%T))<-#@/%'#$%A'*$%*",#$/%-#%"*$)*%<"%L,.L-.%<8-/%*".)7%!G8)% =/+@(/9&(! V! =>9?,#9(! F/1/($<,! U+'%% W!![XB% =/+@(/9&(! "($/% "*% O(<9&LL('%-#L"*:'<-"#% H""=.)</% '#$% <8)% FE>% N#L"*:'<-"#% Q*)/(*-;<-"#% '*)% @""$% /",*()/% "L% ;'<-)#<%-#L"*:'<-"#%'<%$-'@#"/-/g%8<<;gMMAAA7:'(:-..'#7"*@7,=M&'#()*-#L"*:'<-"#M&'#()*-#L"*:'<-"#7'/;Y%8<<;gMMAAA7#8/7,=%!G8)%"==KI!A"==!K+??#$)!I11#<&()&#'B% -/%'#"<8)*%@""$%/",*()%"L% -#L"*:'<-"#7%G8-/%(8'*-<9%-/%*,#%H9%;'<-)#</%A-<8%&!!%<"%;*"6-$)%/,;;"*<%L"*%;'<-)#</%A-<8%&!!7%8<<;gMMAAA7(../,;;"*<7"*@7,=%%HW"==!U#$+9%-/%'%;'<-)#<%/,;;"*<%'//"(-'<-"#%%8<<;gMMAAA7,=(..L"*,:7"*@7,=M%%%=>9?,#9(!I11#<&()&#'B%%8<<;gMMAAA7.9:;8":'/7"*@7,=M%!!!U/$)&L&)>!&"#/-$)*'<-"#%"L%L)*<-.-<9%;*)/)*6'<-"#%/8",.$%H)%:'$)%L"*%<8"/)%"L%*);*"$,(<-6)%'@)%!!%% %

Page 10: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

10

EFTIEOTDE!FT"GOOTD.IECGDK!

%

U&$1)!=&'/!E$/()9/')!

Q$&'<&?L/1%

G8)%L-*/<%$)(-/-"#%<"%H)%:'$)%-#%&!!%-/%A8)<8)*%<8)%;'<-)#<%*)P,-*)/%<8)*';9%'<%<8)%<-:)%"L%-#-<-'.% $-'@#"/-/7% G8)%$-/)'/)% /8"A/%)Y<*):)%8)<)*"@)#)-<9% -#% -</%;*)/)#<'<-"#%'#$% *'<)%"L%;*"@*)//-"#B% '#$% <8)*)% -/% #"% )6-$)#()% <8'<% )'*.9% <*)'<:)#<% "L% '/9:;<":'<-(% "*% /<'H.)%$-/)'/)%-:;*"6)/%."#@4<)*:%/,*6-6'.7%

M&'/)!1)(*/!I!?()&/')1!@)#)*'..9%$"%#"<%#))$%<*)'<:)#<7%><'@)%?%;'<-)#</%A8"%$)6).";%?NE?%"*%NGQ%-#%<8)%'H/)#()%"L%$-/)'/)%;*"@*)//-"#%/8",.$%H)%<*)'<)$%-#%<8)%/<'#$'*$%A'9%L"*%<8)%',<"-::,#)% ;8)#":)#"#% H,<% $"% #"<% *)P,-*)%(9<"*)$,(<-6)% <8)*';97% ?./"B%89;"@'::'@."H,.-#'):-'%-/%#"<%'#%-#$-('<-"#%L"*%<8)*';97%

G8"/)% ;'<-)#</% *)P,-*-#@% #"% -#-<-'.% <8)*';9% /8",.$% H)% :"#-<"*)$% '<% ';;*";*-'<)% -#<)*6'./%'(("*$-#@%<"%A)..H)-#@%'#$%<8)%<*)#$%-#%H.""$%(",#</%m%/"%('..)$%`R()<,!('%!R(&)a7%Q'<-)#</%A-<8% )'*.9% &!!% /8",.$% H)% *)6-)A)$% '<% .)'/<% <A-()% A-<8-#% <8)% L-*/<% 9)'*% L*":% $-'@#"/-/% <"%'//)//% <8)% *'<)% "L% $-/)'/)% ;*"@*)//-"#7% % K"*% <8"/)%A-<8% /<'H.)% $-/)'/)B% ;'*<-(,.'*.9% -L% <8)9%8'6)% r@""$% *-/=D% (.-#-('.% '#$M"*% .'H"*'<"*9% L)'<,*)/B% :"#-<"*-#@% ('#% H)% )Y<)#$)$% <"% '#%'##,'.% (8)(=7% G8-/% :'9% H)% ;)*L"*:)$% -#% ;*-:'*9% ('*)B% -#% 8"/;-<'.% (.-#-(/% "*% H9% $-/<'#()%:"#-<"*-#@% /(8):)/% W/,(8% '/% <8)% *):"<)% Q'<-)#<% T"#-<"*-#@% Q*"@*'::)% s*QTQt% H)-#@%;-."<)$%'<%C'*</%E)'.<8%FE>%G*,/<X7%%

%

C'%&<()&#'1!0#$!)$/()9/')%

• Q$#*$/11&;/!M&'/)!1)(*/!I!('%!M&'/)!1)(*/!M%

• F"#%',<"-::,#)%'#'):-'%'#$M"*%<8*":H"(9<";)#-'%

• !JG% "L% ^% 20% :"#<8/% '#$% "<8)*% -#$-('<-"#/% "L% ;*"@*)//-"#% W#)AM-#(*)'/-#@%#"$)/M"*@'#":)@'.9X%"*%$)(*)'/-#@%8'):"@."H-#M;.'<).)</%

• .9:;8'$)#";'<89%WH,.=9B%\21(:X%M%/;.)#":)@'.9%

• C%/9:;<":/%%

• ?NE?%"*%NGQ%;""*.9%*)/;"#/-6)%<"%/<'#$'*$%<8)*';9%

• M&'/)! 1)(*/! "! A#$! F(&! 1)(*/! C8B! '#'):-'% '#$M"*% <8*":H"(9<";)#-'% /)("#$'*9% <"%:'**"A%-#L-.<*'<-"#%-/%'#%-#$-('<-"#%L"*%<*)'<:)#<%%

%

! !

Page 11: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

11

Q$/N)$/()9/')!<#'1&%/$()&#'1!%

• Q'<-)#<%L'(<"*/g%?@)B%Q>B%("4:"*H-$-<-)/B%*)#'.%L,#(<-"#%%

• J-/)'/)% *).'<)$% L'(<"*/g% /)6)*-<9% "L% /9:;<":/B% /;))$% "L% ;*"@*)//-"#B% ;*"@#"/<-(%%L'(<"*/%W)/;7%(*+,%'H#"*:'.-<-)/X%%

• G*)'<:)#<% *).'<)$% L'(<"*/g% $)@*))% '#$% $,*'<-"#% "L% *)/;"#/)% <"% ;*-"*% <8)*';9B%("#<*'-#$-('<-"#/%'#$%/-$)4)LL)(</%

• Q'<-)#</% *)()-6-#@% ?+$&'/N('(L#*+/1S! :/'%(9+1)&'/! #$! (L/9)+X+9(:% /8",.$% 8'6)%&$$(%&()/%!:L##%!?$#%+<)17% G8-/% /8",.$%H)% *)@-/<)*)$% -#% ."('.% <*,/<% H.""$%H'#=% '#$%<8)%;'<-)#<%@-6)#%';;*";*-'<)% -#L"*:'<-"#%'#$%'#%'.)*<%('*$% -#%('/)%<8)9%/8",.$%H)%'$:-<<)$%<"%'#"<8)*%8"/;-<'.%

!

U&$1)!L&'/!),/$(?>!$/*&9/'1%%

• TL&*&:L/!?()&/')1!1,#+L%!:/!/')/$/%!&')#!<L&'&<(L!)$&(L1!

• U"F! W';;*"6)$% H9% FN&h% u,.9% 011]B% G?% 2USX% L"*% L-<<)*% W+b4+bX% ;'<-)#</%A-<8% #"%'H#"*:'.-<9%"L%GQ3R%W(',<-"#%-#%;'<-)#</%A-<8%*)#'.%-:;'-*:)#<X%

• ",L#$(9:+<&L! R&),! (')&N".62! (')&:#%>! A/*! F&)+Y&9(:S! G0()+9+9(:! #$!G:&'+)+X+9(:B!L"*%.)//%L-<%W>!bO4+bX%;'<-)#</%A-<8%#"%'H#"*:'.-<9%"L%(*+,7%+-6)#%-::-#)#<%FN&h%';;*"6'.B%H"<8%G0()+9+9(:%'#$%G:&'+)+X+9(:%:'9%H)%;*)L)*'H.)%<"%F&)+Y&9(:%

• M/'%(9+1)&'/! Z! F&)+Y&9(:! L"*% -#<)*:)$-'<)% ;'<-)#</% W#"<% L-<% L"*% K&[X7! [)#'.%-:;'-*:)#<%-/%#"<%'#%'H/".,<)%("#<*'-#$-('<-"#%<"!M/'%(9+1)&'/7%

• IL/9)+X+9(:!Z[N!,&*,!%#1/!1)/$#&%1%L"*%;'<-)#</%A-<8%'H#"*:'.-<-)/%"L%(*+,%%

• ILL! ?()&/')1! 1,#+L%! :/! <#'1&%/$/%! 0#$! (;(&L(:L/! 0$#')NL&'/! 1)+%&/1! /*! U=ICF! ('%!F&I=EG%

• I<</11!)#!(*/')1!#'!".U!1,#+L%!:/!$/;&/R/%!AC:$+)&'&:!#$!C%/L(L&1&:ZF&)+Y&9(:B%

!

TL&9&'()&#'!#0!OF.[O(&')/'('</["#'1#L&%()&#'!

• b,</-$)%"L%(.-#-('.%<*-'./B%<8)*)%-/%#"%-#$-('<-"#%<"%*",<-#).9%'<<):;<%T[J%)*'$-('<-"#7%ILL!?()&/')1!1,#+L%!:/!<#'1&%/$/%!0#$!(;(&L(:L/!1)+%&/1!1)+%&/1!/*!JI=I"EC"4%

• b,</-$)% "L% (.-#-('.% <*-'./B% <8)*)% -/% #"% -#$-('<-"#% L"*% "#@"-#@%9(&')/'('</% <8)*';9%L".."A-#@%L-*/<%.-#)%<*)'<:)#<%

• ?/%&!!%*):'-#/%-#(,*'H.)%A-<8%(,**)#<%(8):"4-::,#"<8)*';9B%("#/".-$'<-"#%A-<8%'#%

Page 12: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

12

(LL#*/'/&<! )$('1?L(')% /8",.$% H)% ("#/-$)*)$% -#% $%%% L-<% 9",#@)*% ;'<-)#</% W^53% 9)'*/X%A-<8%(*+,%$).)<-"#M:,<'<-"#%%'#$%*)L*'(<"*9%<"%L.,$'*'H-#)%W#"%*)/;"#/)%"*%*).';/)%

A-<8-#%5%:"#<8/%"*%<8"/)%A8"%*).';/)%A-<8-#%0S%:"#<8/%"L%L.,$'*'H-#)7%

F/1?#'1/!(11/119/')!

n&[% W(":;.)<)% *):-//-"#Xg% '..% "L% <8)% (*-<)*-'% 8'6)% <"% H)% :)<B% '#$% ;'<-)#</% 8'6)% <"% .'(=%$-/)'/)4*).'<)$% ("#/<-<,<-"#'.% /9:;<":/Z% &[-% -/% '% ('<)@"*9% $)L-#)$% H9% L'-.,*)% <"% *)("6)*%/'<-/L'(<"*9%(",#</%H,<%"<8)*%(*-<)*-'%L"*%&[%'*)%:)<Z%Q[%W;'*<-'.%*):-//-"#Xg%'<%.)'/<%<A"%"L%<8)%(*-<)*-'%"L%@*",;%?%;.,/%"#)%"L%<8)%(*-<)*-'%"L%@*",;%C%8'6)%<"%H)%:)<Z%>J%-/%'H/)#()%"L%QJ%'#$%L'-.,*)%<"%'(8-)6)%'%Q[%

% % % % % % % !

K/<#'%!L&'/!('%!1+:1/\+/')!),/$(?>!%%

• G*)'<:)#<% (8"-()/% L".."A-#@% -#-<-'.% <*)'<:)#<% $);)#$% "#% *)/;"#/)% <"% L-*/<% .-#)%<8)*';9% '#$% <".)*'H-.-<97% NL% <8)% *)/;"#/)4$,*'<-"#% <"% L-*/<% .-#)% <8)*';9%A'/% @*)'<)*%<8'#%"#)%9)'*B%<8)#%2/<%.-#)%<*)'<:)#<%('#%H)%*);)'<)$%%%

• TL&*&:L/!?()&/')1!1,#+L%!:/!/')/$/%!&')#!<L&'&<(L!)$&(L1!

• U"F!:'9%H)%("#/-$)*)$%L"*%*).';/)$M*)L*'(<"*9%;'<-)#</%/Y</?)!A8)#%*).';/)%"((,*/%A-<8-#% 0S% :"#<8/% L".."A-#@% '% ;*)6-",/4L.,$'*'H-#)% *)@-:)#% "*% -L% *)L*'(<"*9% <"%UL+%($(:&'/% W*).';/)$% ^% 5% :"#<8/% "L% <*)'<:)#<X% "*% -L% ;*)6-",/.9% <*)'<)$% A-<8%

Q($(9/)/$! "F]! QF! Q.!

!9:;8'$)#";'<89%% F"#)%\%273%(:%% J)(*)'/)%v%31V% N#(*)'/)%v%31V%

E);'<":)@'.9% F"#)% J)(*)'/)%v%31V% N#(*)'/)%v%31V%

>;.)#":)@'.9% F"#)% J)(*)'/)%v%31V% N#(*)'/)%v%31V%

C.""$%!9:;8"(9<)/% \%S111Mw.% J)(*)'/)% v% 31V% L*":%H'/).-#)%

N#(*)'/)%v%31V%"6)*%H'/).-#)%

T'**"A% F"*:"()..,.'*B% ^% R1V%.9:;8"(9<)/B% % #"% C4.9:;8"-$%#"$,.)/%

31V% *)$,(<-"#% -#%:'**"A%-#L-.<*'<)%

"*%C4.9:;8"-$%#"$,.)/%

%

Q.'<).)<%(",#<% \%2117111Mw.% \% 2117111Mw.% "*%-#(*)'/)% v% 31V% "6)*%H'/).-#)%

J)(*)'/)% "L% v% 31V% L*":%H'/).-#)%/)("#$'*9%<"%&!!%

E'):"@."H-#%% \%2271%@M$.%% \% 22% @M$.% "*% -#(*)'/)% v%31V%"6)*%H'/).-#)%

J)(*)'/)% "L% \% 0% @M$.% % L*":%H'/).-#)%/)("#$'*9%<"%&!!%

F),<*";8-./% \2311Mw.% \2311Mw.% "*% \31V%-:;*"6):)#<% "6)*%H'/).-#)%

%

Page 13: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

13

F&)+Y&9(:%WFN&h%';;*"6)$%u,.9%0121X%!

• M/'%(9+1)&'/!Z!F&)+Y&9(:%-/%';;*"6)$%L"*%*).';/)$%<8)*';9%

• G8"/)%A8"%L'-.%<"%*)/;"#$%<"%UL+%($(:&'/4("#<'-#-#@%L-*/<%.-#)%<8)*';9%"*%A8"%8'6)%'%(*+,%$).M:,<'<-"#%/8",.$%*)()-6)%IL/9)+X+9(:!<8)*';9%A-<8%"*%A-<8",<%,&*,!%#1/!9/),>L!?$/%'&1#L#'/%%

• P.OQdM4% F&)+Y&9(:B% %/Y(9/),(1#'/ZF&)+Y&9(:B% F&)+Y&9(:% '."#)B% 1?L/'/<)#9>%'#$%$(%&#),/$(?>%:'9%'..%H)%("#/-$)*)$%'/%;'..-'<-6)%<8)*';9%L"*%.'<)4/<'@)%*)L*'(<"*9%;'<-)#</%

• F)A%@)#)*'<-"#%<8)*';-)/%W/:'..%:".)(,.)%C&[%'#$%"<8)*%-#8-H-<"*/B%#)A%'#<-4&J01%'#<-H"$-)/X% 8'6)% /8"A#% )Y()..)#<% *)/,.</% -#% (.-#-('.% <*-'./% '#$% '*)% .-=).9% <"% H)(":)%'6'-.'H.)%-#%<8)%_q%-#%<8)%#)Y<%240%9)'*/7%C%/L(L&1&:%-/%.-()#/)$%'#$%(,**)#<.9%'6'-.'H.)%<8*",@8%<8)%&JK7%C:$+)&'&:% -/%'./"%.-()#/)$%'#$%(,**)#<.9%'6'-.'H.)%<8*",@8%<8)%&JK7%C"<8%'*)%)Y;)(<)$%<"%H)%)6'.,'<)$%H9%FN&h%-#%0123%

• ?..%;'<-)#</% /8",.$%H)%("#/-$)*)$% L"*%';;*";*-'<)% *).';/)$M*)L*'(<"*9%'#$%8-@8% *-/=%W(*+,%'H#"*:'.-<-)/X%(.-#-('.%<*-'./%

^4!ILL#*/'/&<!K"E%%

• h,*";)'#%+*",;% L"*%C.""$%'#$%T'**"A%G*'#/;.'#<'<-"#% WhCTGX%0115% *)("::)#$/%<8'<%'.."@)#)-(% <*'#/;.'#<'<-"#% -/%'% *)'/"#'H.)%";<-"#% L"*% L-<%;'<-)#</%A-<8%8-@8%*-/=%L)'<,*)/g%

o %'H#"*:'.-<-)/%"L%GQ3R%-#%L-*/<%"*%/,H/)P,)#<%*):-//-"#%

o %F"#% *)/;"#/)% "*% )'*.9% *).';/)% WA-<8-#% 20% :"#<8/X% 'L<)*% ;,*-#)% '#'."@,)4("#<'-#-#@%<8)*';9%%

o [).';/)% A-<8-#% 0S% :"#<8/% 'L<)*% ;,*-#)% '#'."@,)% (":H-#'<-"#% (8):"4-::,#"<8)*';9%%

• Q'<-)#</% /8",.$% H)% *)L)**)$% )'*.9% <"% '% ."('.% <*'#/;.'#<% ()#<*)% A-<8% ';;*";*-'<)%)Y;)*<-/)%

• ?,<"."@",/% >&G% -/% #"% ."#@)*% *)("::)#$)$% )Y();<% -#% ('/)/% "L% [-(8<)*/%<*'#/L"*:'<-"#%'/%'#%'.<)*#'<-6)%<"%'.."4>&G%L"*%("#/".-$'<-"#%'L<)*%(8):"<8)*';9%

%

F&<,)/$1!)$('10#$9()&#'!

• b((,*/%-#%'H",<%R421V%&!!%;'<-)#</%%

• _/,'..9%*';-$%;*"@*)//-"#%-#%'%/-#@.)%#"$'.%/-<)%'((":;'#-)$%H9%'%*-/)%-#%!JE%

• T'9%'./"%,#$)*@"%<*'#/L"*:'<-"#%-#%CTB%&F>%"*%"*@'#/%W.-6)*B%=-$#)9/X%%%

Page 14: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

14

• G*)'<:)#<%b;<-"#/%-#(.,$)-!%

• TL&*&:L/!?()&/')1!1,#+L%!:/!/')/$/%!&')#!<L&'&<(L!)$&(L1!

o "PGQ!<9;)%*)@-:)#%d%$&)+Y&9(:!%

o QL()&'+9!mH'/)$%*)@-:)#%dM4%$&)+Y&9(:!%%

o &8"-()%-/%$);)#$)#<%"#%;*)6-",/%<*)'<:)#<B%@)#)*'.%L-<#)//%"L%;'<-)#<%)<(%'#$%/8",.$%H)%$)(-$)$%"#%'#%-#$-6-$,'.%H'/-/%%

o ?..%(8):"/)#/-<-6)%;'<-)#</%/8",.$%<8)#%H)%("#/-$)*)$%L"*%("#/".-$'<-"#%A-<8%',<"."@",/%"*%'.."@)#)-(%E>&G7%

MN</LL!Q$#L>9?,#<>)&<!=>9?,#<>)&<!=/+@(/9&(!

• k)*9%*'*)%'@@*)//-6)%.),='):-'%A-<8%;""*%/,*6-6'.%%• T"*;8"."@9%'#$%-::,#";8)#"<9;)%$-/<-#(<%L*":%&!!%• E-@8%OC&B%:'//-6)%/;.)#":)@'.9B%:-#-:'.%.9:;8'$)#";'<89%• GQ3R%$).M:,<'<-"#%-#%,;%<"%31V%• ?//)//:)#<%'#$%:'#'@):)#<%'/%L"*%&!!%• %N#$,(<-"#%<*)'<:)#<%A-<8%K&[%"*%C[%-L%#"%GQ3R%$).B%'.):<,l,:'H%-L%GQ3R%'H#"*:'.-<9%• &"#/".-$'<-"#%A-<8%>&G%-#%).-@-H.)%;'<-)#</%• %>;.)#)(<":9%:'9%H)%H)#)L-(-'.%-#%*)/-/<'#<%('/)/%• >,;;"*<-6)%('*)%'/%L"*%&!!%

%

%

O('(*/9/')!#0!%&1/(1/!$/L()/%!<#9?L&<()&#'1!

I+)#&99+'/!P(/9#L>)&<!I'(/9&(!#$!E,$#9:#<>)#?/'&(!

• ?,<"-::,#)%8'):".9<-(%'#'):-'%-/%*);"*<)$%-#%21401V%"L%&!!%;'<-)#</B!'#$%NGQ%-#%043V7%Q[&?%'#$%',<"4-::,#)%#),<*";)#-'%'*)%*'*)*%H,<%;*"H'H.9%,#$)*4*)("@#-/)$%

• ?NE?%"*%NGQ%/8",.$%H)%<*)'<)$%H)L"*)%$)(-$-#@%A8)<8)*%<8)*';9%L"*%&!!%-/%#))$)$%

• Q'<-)#</% A-<8% A'*:% ?NE?% "*% NGQ% /8",.$% H)% <*)'<)$% '(("*$-#@% <"% @,-$).-#)/% L"*%-$-";'<8-(%?NE?%"*%NGQg%

o Q*)$#-/"."#)%'<%2%:@M=@%H"$9%A)-@8<%;)*%$'9%L"*%04S%A))=/B%<';)*-#@%"LL%"6)*%/)6)*'.%A))=/7%%

o K"*% NGQB% NkN+% 2@M=@% '/% '% /-#@.)% -#L,/-"#% W*)/;"#/)/% '*)% <*'#/-)#<X% "*% 17SM=@%"6)*% 3% $'9/% ('#% H)% ,/)$% -L% -::)$-'<)% *)/;"#/)% -/% *)P,-*)$% W)@% H)L"*)%/,*@)*9X7%%

o &9(."/;"*-#)% ?% "*%TTK%:'9% H)% -#$-('<)$% -#% *)/-/<'#<% ('/)/% "*% <"%:'-#<'-#%*)/;"#/)%'#$%'.."A%A-<8$*'A'.%"L%/<)*"-$/%

o [-<,Y-:'H% RU3% :@M:0% A))=.9% Y% S45% W/":)% /<,$-)/% 8'6)% ,/)$% 211:@%*-<,Y-:'H%A))=.9%A-<8%@""$%)LL)(<X%

Page 15: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

15

o &":H-#'<-"#%<8)*';9%A-<8%*-<,Y-:'HB%(9(.";8"/;8':-$)%'#$%$)Y':)<8'/"#)%('#%H)%,/)$%-#%*)/-/<'#<%('/)/%

o >;.)#)(<":9%o ?6"-$% *)4<*)'<:)#<% A-<8% L.,$'*'H-#)% -#% ;'<-)#</% A-<8% '% ;*)6-",/% 8-/<"*9% "L%

;,*-#)%'#'."@,)%*).'<)$%?NE?%"*%NGQ7%o GQb4[%'@"#-/</%%W).<*":H";'@M*":-;."/<-:X%('#%H)%8).;L,.%-#%*)/-/<'#<%NGQ7%

%

%

C'0/<)&#'%

• N#L)(<-6)%(":;.-('<-"#/%'*)%'%("::"#%(.-#-('.%;*"H.):%'#$%'((",#<%L"*%<8)%:'I"*-<9%"L%&!!%$)'<8/%

• >,/();<-H-.-<9%-/%:,.<-L'(<"*-'.%'#$%$,)%<"%<8)%$-/)'/)%-</).L%'#$%'/%'%*)/,.<%"L%<8)*';9%'#$% -#(.,$)/% 89;"@'::'@."H,.-#'):-'B% #),<*";)#-'B% -:;'-*)$% G% '#$%#'<,*'.% =-..)*%()..%L,#(<-"#%'#$%$)L)(<-6)%(":;.):)#<%'(<-6-<9%

• T"/<% -#L)(<-"#/% '*)% H'(<)*-'.% H,<% L,#@'.B% 6-*'.% '#$% ";;"*<,#-/<-(% -#L)(<-"#/% '*)%-#(*)'/-#@.9%;*)6'.)#<%A-<8%#)A)*%<*)'<:)#</%W;,*-#)%'#'."@,)/B%'.):<,l,:'H%'#$%:)<89.%;*)$#-/"."#)X%

• ?..% ;'<-)#</% /8",.$% *)()-6)% 6'((-#'<-"#% '@'-#/<% )#(';/,.'<)$% H'(<)*-'%W;#),:"("((,/B%ENCX%'#$%'##,'.% -#L.,)#l'%H,<%FbG% .-6)%6'((-#'<-"#/% W-#(.,$-#@%<8)%(,**)#<%/8-#@.)/%6'((-#)X%

% %

Page 16: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

16

?$6-()%"#%<8)%,/)%"L%/;)(-L-(%6'((-#)/%-/%'6'-.'H.)%'<%%8<<;gMMAAA7$87@"67,=M)#MQ,H.-('<-"#/'#$/<'<-/<-(/MQ,H.-('<-"#/MQ,H.-('<-"#/Q".-(9?#$+,-$'#()MJEx1U]]2U%

• %

• ?..% -#L)(<-"#/% /8",.$% H)% <*)'<)$% 6-@"*",/.9B% )/;)(-'..9% -#% <8"/)% ;'<-)#</% *)()-6-#@%<*)'<:)#<% '#$M"*% A-<8% '% ;*-"*% 8-/<"*9B% % '#$% ;'<-)#</% @-6)#% -#L"*:'<-"#% <"% ("#<'(<%<8)-*%$"(<"*%"*%<8)%&F>%'<%<8)%L-*/<%/-@#%"L%-#L)(<-"#%L"*%'$6-()%

• _;% <"% U1V% "L% ;'<-)#</% A-<8% &!!% 8'6)% 89;"@'::'@."H,.-#'):-'% '#$% NkN+% -/%*)("::)#$)$% L"*% <8"/)% A-<8% *)(,**)#<% /)6)*)% -#L)(<-"#/$)/;-<)% ;*";89.'(<-(%'#<-H-"<-(/7%

• Q'<-)#</%*)()-6-#@%;,*-#)4'#'."@,)%("#<'-#-#@%(8):"<8)*';9%A-..%,/,'..9%*)()-6)%Q&Q%'#$% 8)*;)/% ;*";89.'Y-/7% N#% '$$-<-"#% <8"/)% ;'<-)#</% *)()-6-#@% 8-@8% $"/)% /<)*"-$/%/8",.$% './"%8'6)% '#<-4L,#@'.% ;*";89.'Y-/% '#$% <8"/)% *)()-6-#@% '.):<,l,:'H% *)P,-*)%A))=.9%:"#-<"*-#@%L"*%&Tk%*)'(<-6'<-"#%

• G8)% ,/)% "L% +4&>K% /8",.$% H)% ("#/-$)*)$% -#% ;'<-)#</% A-<8% ;*"."#@)$M/)6)*)%#),<*";)#-'%;"/<%(8):"<8)*';9%

%

K+??#$)&;/!<($/!('%!$/,(:&L&)()&#'!!!!

FTPIMC=CEIECGD!ID.!KHF8C8GFKPCQ!N//,)/% -#% *).'<-"#% <"% *)8'H-.-<'<-"#B% ."#@% <)*:%("#/)P,)#()/%"L% <*)'<:)#<%'#$%/,*6-6"*/8-;%/8",.$% H)%:"#-<"*)$% <8*",@8",<% <8)% ;'<-)#<% ;'<8A'9% '#$% [email protected]@8<)$% <"% <8)% ';;*";*-'<)%?..-)$%E)'.<8%Q*"L)//-"#'./% -L% *)P,-*)$7% >,*6-6"*/8-;% -//,)/% ('#% *).'<)% <"% <8)%)LL)(</% "L% <8)%$-/)'/)%;*"()//%'#$%M%"*%:'#'@):)#<%"L%."#@4<)*:%'$6)*/)%)LL)(</%"L%<*)'<:)#<7%%%[)L)**'./%-#(.,$)g!

• Q89/-"<8)*';-/<M% "((,;'<-"#'.% <8)*';-/<% WL'<-@,)% :'#'@):)#<B% *)8'H-.-<'<-"#B%*)$,()$%:"H-.-<9X!

• $-)<-<-'#%-L%/9:;<":/%-:;'(<-#@%"#%-#<'=)M#,<*-<-"#'.%/<'<,/%)/;)(-'..9%-#%('/)/%"L%+N%$-/<,*H'#()/%'#$%:,("/-<-/B%A)-@8<%."//%

• /;))(8% '#$% .'#@,'@)% <8)*';-/<% WA)-@8<% ."//B% $9/;8'@-'% "*% ("#()*#/% *)@'*$-#@%'/;-*'<-"#X%

• -#L"*:'<-"#% .)'L.)</% "#% #),<*";)#-(% $-)</% '#$% r)'<-#@% A)..% A-<8% ('#()*D% /8",.$% H)%:'$)%'6'-.'H.)%

%?#9%;'<-)#<%)Y;)*-)#(-#@%"*%*);"*<-#@%*)$,()$%:"H-.-<9%'#$M"*%'H-.-<9%<"%;)*L"*:%'(<-6-<-)/%"L%$'-.9%.-6-#@B%/8",.$%H)%*)L)**)$%L"*%"((,;'<-"#'.%<8)*';9%'#$%;89/-"<8)*';9%'//)//:)#<%% %

Page 17: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

17

%%NL%'#%-#4;'<-)#<g%

o ?#9% ;'<-)#<% /8"A-#@% /-@#/% "L% *)/;-*'<"*9% $-/<*)//% /8",.$% H)% *)L)**)$% L"*%*)/;-*'<"*9% ;89/-"<8)*';9% '//)//:)#<% -#% '(("*$'#()% A-<8% ."('.% "#4('..%@,-$).-#)/B%,#.)//%"L%"6)*<%:)<'H".-(%(',/)%

o ?%/(*))#-#@%<"".%L"*%'//)//:)#<%"L%$-)<'*9%-//,)/%/8",.$%H)%(":;.)<)$%A))=.9%'#$%-L%-//,)/%-$)#<-L-)$B%'%*)L)**'.%<"%/;)(-'.-/<%$-)<-<-'#%:'$)%

%?#9% ;'<-)#<% /8"A-#@% /-@#/% "L% #"#4'(,<)% H*)'<8.)//#)//% /8",.$% H)% *)L)**)$% <"% /;)(-'.-/<%"((,;'<-"#'.%<8)*';9%"*%;89/-"<8)*';9%L"*%'//)//:)#<%'#$%-#<)*6)#<-"#%%%[)L)**'.%L"*%>;)(-'.-/<%$-)<-)<-(%-#;,<%/8",.$%H)%:'$)%-#%<8)%L".."A-#@%-#/<'#()/g%%

- ?#9%;'<-)#<%A-<8%#),<*";)#-'%/8",.$%H)%;*"6-$)$%A-<8%-#L"*:'<-"#%'#$%)$,('<-"#%"#%<8)%#),<*";)#-(%$-)<%'#$%8'6)%'%*)L)**'.%:'$)%<"%'%/;)(-'.-/<%$-)<-<-'#%

- NL%'*<-L-(-'.%L))$-#@%-/%H)-#@%("#/-$)*)$B%'%*)L)**'.%<"%<8)%/;)(-'.-/<%$-)<-<-'#%/8",.$%H)%:'$)%%

- ?#9%;'<-)#<%A-<8%:,("(-<-/%/8",.$%H)%*)L)**)$%L"*%$-)<)<-(%'//)//:)#<%'/%A)..%'/%L"*%/;)(-'.-/<%/;))(8%'#$%.'#@,'@)%'//)//:)#<%

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q)9%O"*=)*%A-<8%<8)%;'<-)#<%'#$%'%(";9%/)#<%<"%<8)%+Q%'#$%<8)%;'<-)#<7%Q'<-)#</%A8"%*):'-#%,#<*)'<)$%"#%A'<(8%'#$%A'-<%L".."A%,;%/8",.$%'-:%<"%8'6)%'#%'##,'.%EF?7%

Q)";.)% /8",.$% H)% "LL)*)$% '(()//% <"% '% 8)'.<8% '#$% A)..H)-#@% (.-#-(% '<% <8)% )#$% "L%<*)'<:)#<7%%G8-/%/8",.$%;*"6-$)%-#L"*:'<-"#%<"%)#'H.)%'%;)*/"#%<"%/).L4:'#'@)%'#9%)Y;)(<)$%("#/)P,)#()/% "L% <8)-*% ('#()*% '#$% -</% <*)'<:)#<B% '/% A)..% '/% @)#)*'.% 8)'.<8% ;*":"<-"#%-#L"*:'<-"#B%-#(.,$-#@%$-)<%'#$%;89/-('.%'(<-6-<97%%%%%%%%%%%

G8)%TJG%",<(":)% L"*:%'#$%(.-#-(% .)<<)*/%A-..% /)*6)% <"% ("::,#-('<)%$-'@#"/-/B% <*)'<:)#<%-#-<-'<-"#%'#$%#)A%.-#)/%"L%<*)'<:)#<%A-<8%<8)%+Q7%!!! !

Page 18: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

18

UG==G_NHQ!IFFIDJTOTDEK!• ><'@)%?%;'<-)#</%A-<8%/<'H.)%$-/)'/)%*)P,-*)%*)6-)A%)6)*9%5420%:"#<8/%$);)#$-#@%"#%

'@)% )<(7% <8-/% ('#% H)% ,#$)*<'=)#% H9% <8)%+Q% -#%:'#9% ('/)/%A-<8% '@*))$% <*-@@)*/% L"*%*)L)**'.%H'(=%<"%<8)%8'):'<"."@9%<)':%

• Q'<-)#</% A-<8% ;*"@*)//-6)% $-/)'/)% A-..% *)P,-*)% :"*)% L*)P,)#<% :"#-<"*-#@% WP% 24R%:"#<8.9X%$);)#$-#@%"#%;'()%"L%(8'#@)%%

• Q'<-)#</%"#%<*)'<:)#<%/8",.$%H)%/))#%"#()%)6)*9%04S%A))=/%• Q'<-)#</%"#%KM_%'L<)*%(":;.)<-"#%"L%<*)'<:)#<%/8",.$%H)%/))#%:"#<8.9%,#<-.%*)("6)*9%

-/%/)(,*)%'#$%<8)#%)6)*9%R45%:"#<8/%$);)#$-#@%"#%(.-#-('.%(-*(,:/<'#()/!• N#(*)'/-#@.9B% $-/<'#()%:"#-<"*-#@% /(8):)/% W/,(8% '/% <8)% *):"<)%Q'<-)#<%T"#-<"*-#@%

Q*"@*'::)%s*QTQt%H)-#@%;-."<)$%'<%C'*</%E)'.<8%FE>%G*,/<X%A-..%H)%'H.)% <"%$).-6)*%L".."A4,;% ('*)% A-<8",<% <8)% ;'<-)#<% #))$-#@% <"% '<<)#$% (.-#-(/B% A8-.)% :'-#<'-#-#@%"6)*/-@8<%L*":%<8)%<)*<-'*9%()#<*)!

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q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

Page 19: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

19

F/0/$/'</1!!C)/<%b+B%+'*$-#)*%?&B%J'6-/%p?B%G*'(9%NB%NHH"</"#%[hB%T'I-$%?B%J9)*%TuB%b/(-)*%J+7%?%/,H/)<%"L%C-#)<%/<'@)%?%&!!%;'<-)#</%A-<8%GQ3R%'H#"*:'.-<-)/%'#$%:,<'<)$%N+Ek%@)#)/%8'6)%/<'H.)%$-/)'/)7%!),=):-'7%011]%u'#Z0RW2Xg0204S7%

C-#)<Bu7!7B% !);";*-)*BT7B% J-@8-)*"B+7B% &8'**"#BJ7B% Jy?<8-/BQ7B% k',@-)*B+7B% C)*'.BE7T7B%F'<'.-Bu7&7B%[';8').BT7B%F-l)<BC7B%i%K"..)l",Bu7f7%W2]UUX%?%(.-#-('.%/<'@-#@%/9/<):%L"*%(8*"#-(%.9:;8"(9<-(%.),=):-'g%;*"@#"/<-(%/-@#-L-('#()7%-$./"0B%S1B%e334e5S7%

&'<"6/=9BJ7B% [-(8'*$/B>7B% T'<,<)/Bh7B% b/(-)*BJ7B% J9)*BT7u7B% C)l'*)/B[7K7B% Q)<<-<<B?7[7B%E':H.-#BG7B% T-..-@'#BJ7O7B% &8-.$Bu7?7B% E':-.<"#BT7>7B% J)'*$)#B&7h7B% >:-<8B?7+7B%C"/'#P,)<B?7+7B% J'6-/Bp7B% C*-<"4C'H';,..)Bk7B% h./)BT7B% O'$)B[7B% i% E-..:)#BQ7% W011UX%?//)//:)#<% "L% L.,$'*'H-#)% ;.,/% (9(.";8"/;8':-$)% L"*% ;'<-)#</%A-<8% (8*"#-(% .9:;8"(9<-(%.),='):-'%W<8)%![K%&!!S%G*-'.Xg%'%*'#$":-/)$%("#<*"..)$%<*-'.7%1$./"#B%RU1B%0R140R]7%

J':.)%[FB%O'/-.%GB%K'-/%K%)<%'.7% N@%k%@)#)%:,<'<-"#%/<'<,/%'#$%&JRe%)Y;*)//-"#%'/%#"6).%;*"@#"/<-(%-#$-('<"*/%-#%(8*"#-(%.9:;8"(9<-(%.),=):-'7%C.""$%2]]]Z]SW5Xg2eS142eSU7%

J)'*$)#%&7%J-/)'/)%/;)(-L-(%(":;.-('<-"#/%"L%&!!7%?>E%h$,('<-"#%>)//-"#B%C.""$%%011e%

K'**)#%GB%u)*":)%+-,/<-#-'#-B%K)#@4G-#@%!-,B%J-:-<*-/%?7%G/-</-='/B%T'*-"#%+7%T'()9B%u':)/%J7% &'6)#'@8B% E)'<8)*% h7% b'=)*6))B% J'6-$% G',//-@B% ?$*-'#% &7% F)A.'#$B%T'*-'% &'.':-#-(-B%?*:'#$% C)#/,//'#B%T-(8').% u)##)*B% u"8#%+7% +*-HH)#% '#$% >':-*% +7% ?@*'A'.7% J-LL)*)#<-'.%'#$% <,:",*% /;)(-L-(% )Y;*)//-"#% "L% &J251% -#% C4()..%:'.-@#'#(-)/7% C.""$% 0122% 22eg% 02US402eR% %

E'..)=BT7B%&8)/"#BC7J7B%&'<"6/=9BJ7B%&'.-@'*-/4&';;-"BK7B%J-@8-)*"B+7B%J"8#)*BE7B%E-..:)#BQ7B%q)'<-#@BT7u7B%T"#</)**'<Bh7B%['-Bq7[7B%i%q-;;/BG7u7% W011eX%+,-$).-#)/% L"*% <8)%$-'@#"/-/%'#$%<*)'<:)#<%"L%(8*"#-(%.9:;8"(9<-(%.),=):-'g%'%*);"*<%L*":%<8)%N#<)*#'<-"#'.%O"*=/8";%"#%&8*"#-(% !9:;8"(9<-(% !),=):-'% ,;$'<-#@% <8)% F'<-"#'.% &'#()*% N#/<-<,<)4O"*=-#@% +*",;%2]]5%@,-$).-#)/7%2%334B%222B%3SS543S357%

E'..)=BT7B% K-/(8)*Bq7B% K-#@)*.)4["A/"#B+7B% K-#=B?7T7B% C,/(8B[7B% T'9)*Bu7B% E)#/).BT7B%E";L-#@)*B+7B%E)//B+7B%6"#B+7_7B%C)*@:'##BT7B%&'<'.'#"Bu7B%p-#l'#-BQ7!7B%&'.-@'*-/4&';;-"BK7B%>)9:",*Bu7K7B% C)**)H-B?7B% u'@)*B_7B% &'l-#BC7B% G*#)#9BT7B% O)/<)*:'##B?7B% O)#$<#)*B&7T7B%h-(88"*/<BC7K7B% ><'-HBQ7B%C,8.)*B?7B%O-#=.)*BJ7B%p)#lBG7B%C"<<(8)*B>7B%[-<@)#BT7B%T)#$-.'BT7B%q#)H'BT7B% J"8#)*BE7B% i% ><-.@)#H',)*B>7% W0121X% ?$$-<-"#% "L% *-<,Y-:'H% <"% L.,$'*'H-#)% '#$%(9(.";8"/;8':-$)% -#% ;'<-)#</%A-<8% (8*"#-(% .9:;8"(9<-(% .),='):-'g% '% *'#$":-/)$B% ";)#4.'H).B%;8'/)%R%<*-'.7%1$./"#B%RU5B%225S422US7%

E':H.-#% GuB%J'6-/% pB%+'*$-#)*%?B%b/(-)*%J+B% ><)6)#/"#% Kq7%_#:,<'<)$% N@%kWEX% @)#)/% '*)%'//"(-'<)$% A-<8% '% :"*)% '@@*)//-6)% L"*:% "L% (8*"#-(% .9:;8"(9<-(% .),=):-'7% C.""$%2]]]Z]SW5Xg2eSe42e3S%

E"A='#$)*BF7B%F""#)B?7T7B%q*';(8"BT7B%F)9:'#BF7B%?:-#",B[7B%?.<)=*,/)B>7B%q"/'*9B&7B%[,8.Bu7B%G'<'."6-(8Bp77%&8"BE7B%T'*-"<<"B?7B%h-/#)*B%T7Q7B%!)A-/B%J7[7B%&8)#BE7>7B%K),)*Bh7u7B%i%&*"#-#Bq7?7W0120X%>hh[%&'#()*%><'<-/<-(/%[)6-)A%2]U34011]%Wk-#<'@)%%011]%Q";,.'<-"#/XB%F'<-"#'.%&'#()*%N#/<-<,<)%7%C)<8)/$'B%TJ78<<;gMM/))*7('#()*7@"6%

Page 20: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

20

q#',LBO7_7B%!-//-(8="6BG7B%?.$'",$B?7B%!-H)*'<-B?7B%!"/()*<'.)/Bu7B%E)*H*)(8<B[7B%u,.-,//"#B+7B%Q"/<#)*B+7B% +)*(8)6'B!7B% +"*'#"6B>7B% C)(=)*BT7B% K*-(=)BE7u7B% E,@,)<BK7B% J).B+7B% NB% q.)-#BQ7B%G*)::).B!7B%T)*=.)Bq7B%i%T"#<-.."BT7%W011]X%Q8'/)%NNN%*'#$":-l)$%/<,$9%"L%H)#$':,/<-#)%(":;'*)$% A-<8% (8."*':H,(-.% -#% ;*)6-",/.9% ,#<*)'<)$% ;'<-)#</% A-<8% (8*"#-(% .9:;8"(9<-(%.),=):-'7%5!-%6.!7./3%&B%0UB%SRUe4SReS7%

%T"*)<"#% QB% q)##)$9% CB% !,('/% +% )<% '.7% h*'$-('<-"#% "L% :-#-:'.% *)/-$,'.% $-/)'/)% -#% C4()..%(8*"#-(% .9:;8"(9<-(% .),=):-'% 'L<)*% '.):<,l,:'H% <8)*';9% -/% '//"(-'<)$% A-<8% ;*"."#@)$%/,*6-6'.7%u%&.-#%b#(".%0113Z0RW2RXg0]U240]U]7%

G':%&>B%>8'#'L).<%GJB%O-)*$'%O+B%?H*,ll"%!kB%k'#%J9=)%J!B%byC*-)#%>B%K)**'I".-%?B%!)*#)*%>?B%!9##%?B%q'9%FhB%q)'<-#@%Tu7%J)%#"6"%$).)<-"#%2U;2R72%(8*"#-(% .9:;8"(9<-(% .),=):-'%/8"A/%/-@#-L-('#<%(.-#-('.%8)<)*"@)#)-<9g% <8)%T7%J7%?#$)*/"#%'#$%T'9"%&.-#-(%)Y;)*-)#()7%C.""$7%011]Z22Sg%]3U45S7!

G"H-#%+B%G8,#H)*@%_B%u"8#/"#%?B%)<%'.7%>":'<-('..9%:,<'<)$%N@%kWEXR402%@)#)/%(8'*'(<)*-l)%'% #)A% /,H/)<% "L% (8*"#-(% .9:;8"(9<-(% .),=):-'7% C.""$7% 0110Z]]g% 00504005S7

Page 21: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

%

% %

!"#$%&'()*+,-"'&.//&

!"#$%&'$(")*(+)'+,&'-,"')

.,/) 0()

1+,2$(3/45)3"'+,&',#)678)#,4,',#)9:;<<)

=$>"$*$%&"')?(+@$#$'5)

A&'%B)&"#)C&$')

D4,-'3E3-&@)FG:)B$>B)#(/,)-,'B548+,#"$/(4(",)

HD4,-'3E3-&@)&2&$4&@4,)2$&)8')&%%,//)/%B,-,I)!#,4&4$/$@GJ$'3K$-&@)

HJ$'3K$-&@)$/)&)1@J),K%43/$("L)$#,4&4$/$@)$/)&2&$4&@4,)2$&)&"),K8&"#,#)&%%,//)

/%B,-,I)

.$(+(0)$&12()$&341(,+5&)!,1&"$(*(6$"&7,2&0$(+(0)$&12()$5&

• 6/')4$",M)9,"#&-3/'$",H0!;N)ODP6Q)?&+)66IL))

!"#• ;B4(+&-@3%$4GJ$'3K$-&@)

HJ$'3K$-&@)$/)&)1@J),K%43/$("I&• ;B4(+&-@3%$4GR*&'3-3-&@&• ;B4(+&-@3%$4GR@$"3'3E3-&@#&

.$(+(0)$&12()$&341(,+5&)!,1&"$(*(6$"&7,2&0$(+(0)$&12()$5&

• S;J)H0!;N)67T):)U345)VWI)38&

• !"#$%&'()%#)*+$)",'()-.)/'0($1)9,"#&-3/'$",GJ$'3K$-&@HJ$'3K$-&@)$/)&)1@J),K%43/$("L)@,"#&-3/'$",)$/)*3"#,#)@5);XSI)

0().,/)

.92,+(0&/%:49,0%1(0&/";<)":()&.9":,19"2)4%&=2")1:"+1&3;1$(+"&>$*,2(19:-&

Page 22: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

22

%

%

?-1&8"$)4-"&

=$>"$*$%&"')?(+@$#$'5)

.,/)0()

?-1&8"$)4-"&.$(+(0)$&12()$5&!,1&"$(*(6$"&7,2&0$(+(0)$&12()$5&• ;B4(+&-@3%$4)

!"#• 9,"#&-3/'$",)Y)J$'3K$-&@)

HJ$'3K$-&@)$/)&)1@J),K%43/$("L)@,"#&-3/'$",)$/)*3"#,#)@5);XSI))

!"#• J$'3K$-&@)Y)!#,4&4$/$@HJ$'3K$-&@)$/)&)

1@J),K%43/$("L)!#,4&4$/$@)$/)*3"#,#)@5);XSI)

!"#

• !@+3'$"$@)HS3"#,#)@5)'B,);XSI)

?-1&8"$)4-"&@A%2-&&!,1&"$(*(6$"&7,2&0$(+(0)$&12()$5&J,'+,&')C$'B)S;JZZ)'B,")=;O)

?-1&8"$)4-"&BA%2-&.$(+(0)$&12()$5&!,1&"$(*(6$"&7,2&0$(+(0)$&12()$5&

• D4,-'3E3-&@)FG:)[X?1))!"#

• !#,4&4$/$@)Y)J$'3K$-&@)HJ$'3K$-&@)$/)&)1@J),K%43/$("L)!#,4&4$/$@)$/)*3"#,#)@5);XSL)@3')%B,%\)%+$',+$&I)

!"#• !@+3'$"$@)HS3"#,#)@5);XS)]$*)678)#,4,'$(")#,2,4(8/^I))

)

A+'&8"$)4-"&

A+'&8"$)4-"&C&)01(D"&12")1:"+1&.$(+(0)$&12()$5)!,1&"$(*(6$"&7,2&0$(+(0)$&12()$5&• D4,-'3E3-&@)HD4,-'3E3-&@)&2&$4&@4,)2$&)8')&%%,//)/%B,-,IFG:)[X?1)

!"#• J$'3K$-&@)Y)!#,4&4$/$@HJ$'3K$-&@)$/)&)1@J),K%43/$("L)!#,4&4$/$@)$/)

*3"#,#)@5);XSI)

!"#

• !@+3'$"$@)HS3"#,#)@5);XSI))

1+,2$(3/45)'+,&',#)678)#,4,',#)9);<<)C$'B)

%B,-('B,+&85)@3')"(')D4,-'3E3-&@)

• D4,-'3E3-&@)FG:)[X?1)

!"#• !@+3'$"$@)HS3"#,#)@5)

;XSI)• !#,4&4$/$@)FJ$'3K$-&@)

HS3"#,#)@5);XS_I)

A+'&8"$)4-"&,2&*2")1"2&E&4)$$()1(,+&.$(+(0)$&12()$5&!,1&"$(*(6$"&7,2&0$(+(0)$&12()$5&&

• X,K&-,'B&/(",)F)J$'3K$-&@)!"#

• [X?1)FG:)J$'3K$-&@)#!"#

• J$'3K$-&@)&4(",`)/84,",%'(-5`)+&#$('B,+&85))

Page 23: Chronic Lymphocytic Leukaemia DRAFT London Cancer Guidelineslondoncancer.org/media/123091/Chronic-Lymphocytic... · 2016-07-06 · !"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271% 3.&00/$/')&(l!.&(*'#1&1!!

!"#$"#%&'#()*%&!!%+,-$).-#)/%0123425%6271%

23

%

FG!HI!J&KLM/>!>=I3!&

Z)B&/)"(')@,,")8+,/,"',#G&88+(2,#)&');&"%,+)XYO)%(--$'',,)'B,+,*(+,),&%B)&884$%&'$(")C$44)+,a3$+,/)%B&$+-&"b/)&%'$(")Y)!;XSJ)&884$%&'$(")*(+)*3"#$">)ZZ))6c)!*)8&'$,"')B&#)S;J)6/')4$",)&/)8,+)!I.K&=>?NO)'B,")+,'+,&'$">)C$'B)S;J)P"#)4$",)$/)(3'/$#,)!I.K&=>?PQ&RS;$%&AT?TIc)1&'$,"')C$44)+,a3$+,)1;O)&884$%&'$(")*(+)*3"#$">c))Pc)!*)8&'$,"')B&#)8+,2$(3/)'+,&'-,"')CB$%B)$"%43#,/)&)4(C,+)#(/,)'B&")%3++,"'45)4$%,"/,#)(*)+$'3K$-&@)&"#G(+)C$'B)%B,-('B,+&85)('B,+)'B&")S;)'B,")/3@/,a3,"')'+,&'-,"')C$'B)S;J)*&44/)C$'B$")!I.K&=>?PQc)1&'$,"')C$44)"(')+,a3$+,)1;O)&884$%&'$(")*(+)*3"#$">c)))&!I.K&=>&A?U&V)209&AT??&9,"#&-3/'$",)$/)+,%(--,"#,#)&/)&")(8'$(")*(+)'B,)*$+/':4$",)'+,&'-,"')(*)%B+("$%)45-8B(%5'$%)4,3\&,-$&)H9$",')/'&>,)9)(+);I)$")8&'$,"'/)*(+)CB(-)*43#&+&@$",)%(-@$"&'$(")%B,-('B,+&85)$/)"(')&88+(8+$&',c))14,&/,)/,,)38)'()#&',);XS)*(+-/)&"#);XS)*3"#$">)%+$',+$&)&')CCCc@43,',ac%(-G%#*))